Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI

NCT05601973 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

60

Enrollment

NETWORK

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Amivantamab
DRUG: Lazertinib
DRUG: Zirabev

Sponsor

ETOP IBCSG Partners Foundation

Collaborators

[object Object]